EUVIMEDEUVIMED entdecken
Crossref

Survival Outcomes With or Without Risk-Reducing Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers

Ashu Gandhi iD, Sacha J Howell iD, Elaine F Harkness iD, Emma Woodward iD, Fiona Lalloo iD, Claire Forde iD, James Harvey, Lyndsey Highton, Nicola Flaum iD, D Gareth Evans iD

Journal of Clinical Oncology · 01.04.2026 · 44 (10) · 874-882

DOI: 10.1200/jco-25-00834 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.04.2026. Verfasst von Ashu Gandhi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, United Kingdom. Hauptthemen laut MEDLINE: Breast Neoplasms, Prophylactic Mastectomy, Genes, BRCA2, Genes, BRCA1. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Many women carrying pathogenic variants (pvs) of BRCA1 and BRCA2 genes (pv BRCA 1/2 ) elect to undergo bilateral risk-reducing mastectomy (BRRM) in the belief that it will improve their overall survival (OS). Although many are satisfied with their decision to undergo BRRM a significant minority exhibit regret. We compared long-term oncology outcomes in women with pv BRCA1/2 choosing BRRM with those choosing a program of imaging surveillance. METHODS All participants were attendees at a regional family history/genetics service and had undergone genetic testing for pv BRCA 1/2 . Carriers of pv BRCA1/2 elected either to undergo BRRM or imaging surveillance as directed by UK national guidance. A prospective cohort design examined OS, breast cancer–specific death, and breast cancer incidence between the study groups. RESULTS A total of 460 women elected to undergo BRRM, while 745 chose surveillance (median age, 37.2 years and 38.5 years, respectively; P = .06). Follow-up totaled 4,652 woman-years after BRRM. Overall annual incidence rate of breast cancer was 2.4%, falling to 0.15% after BRRM, a 94% reduction compared with surveillance alone (log-rank chi-square = 86.1; P < .001). There were nine occult cancers diagnosed at BRRM (2%). Breast cancer–specific deaths were similar in the BRRM and surveillance groups (two and four deaths, respectively; P = .36; 4,634 and 5,419 woman-years of follow-up, respectively). Proportionately, deaths from breast cancer were similar to deaths from ovarian cancer in both treatment groups. CONCLUSION For women electing imaging surveillance over risk-reducing surgery, our results may offer reassurance that their breast cancer–specific survival and OS are unlikely to be compromised. However, breast cancer incidence rates are significantly reduced after BRRM compared with imaging surveillance, which may be important information for women with pv BRCA 1/2 considering BRRM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsProphylactic MastectomyGenes, BRCA2Genes, BRCA1BRCA2 ProteinBRCA1 ProteinMastectomyHumansFemaleAdultProspective StudiesGenetic Predisposition to DiseaseMiddle AgedHeterozygoteIncidence

Substanzen

BRCA2 protein, humanBRCA2 ProteinBRCA1 protein, humanBRCA1 Protein

Autor:innen und Institutionen

  • Division of Cancer Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, United Kingdom.
  • Manchester University Hospitals, Manchester, United Kingdom.
  • Manchester Academic Health Sciences Centre & Manchester Breast Centre, University of Manchester, Manchester, United Kingdom.
  • Christie Hospital NHS Foundation Trust, Manchester, United Kingdom.
  • Division of Informatics, Imaging and Data Sciences, The University of Manchester, Manchester, United Kingdom.
  • Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom.

ORCID-Profile: Ashu Gandhi, Sacha J Howell, Elaine F Harkness, Emma Woodward, Fiona Lalloo, Claire Forde, Nicola Flaum, D Gareth Evans

Zitieren

APA

Gandhi, A., Howell, S. J., Harkness, E. F., Woodward, E., Lalloo, F., Forde, C., Harvey, J., Highton, L., Flaum, N., & Evans, D. G. (2026). Survival Outcomes With or Without Risk-Reducing Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers. Journal of Clinical Oncology, 44(10), 874-882. https://doi.org/10.1200/jco-25-00834

Vancouver

Gandhi A, Howell SJ, Harkness EF, Woodward E, Lalloo F, Forde C, et al. Survival Outcomes With or Without Risk-Reducing Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers. Journal of Clinical Oncology. 2026;44(10):874-882. doi:10.1200/jco-25-00834

BibTeX
@article{Gandhi2026,
  author = {Gandhi, Ashu and Howell, Sacha J and Harkness, Elaine F and Woodward, Emma and Lalloo, Fiona and Forde, Claire and Harvey, James and Highton, Lyndsey and Flaum, Nicola and Evans, D Gareth},
  title = {Survival Outcomes With or Without Risk-Reducing Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {10},
  pages = {874--882},
  doi = {10.1200/jco-25-00834}
}
Kostenlos starten →